Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®

NCT03447132 is registered in ClinicalTrials.gov with International Cancer Research Group, United Arab Emirates as lead sponsor.

NCT NCT03447132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03447132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®
Lead sponsor
International Cancer Research Group, United Arab Emirates
Phase
Phase 3
Overall status
Completed
Start date
December 20, 2017
Completion date
July 20, 2021
Enrollment
354 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm female